Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Pfizer Japan Mulls Over Alternative Manufacturing Route Following Suspension of Methotrexate Production in Germany
April 19, 2019
- SanBio Unveils Positive PII Data for SB623 in Traumatic Brain Injury
April 18, 2019
- Sanofi Pushing Drugs’ Added Values to Secure Patient Access amid Rising Awareness for Economic Efficiency
April 18, 2019
- Bayer, Hokkaido Pref. Join Forces to Tackle Life Style Diseases
April 18, 2019
- Japan Pharma Market Grew 87.1% in 30 Years of Heisei Era: IQVIA
April 18, 2019
- With Ozempic Listing in Limbo, Novo Japan Chief Says Single-Dose Device Launch Unlikely This Year
April 17, 2019
- Evenity Heavily Pitched via In-Clinic Seminars in February: Anterio
April 17, 2019
- Toa Eiyo Grants China Marketing Rights for Bisono Tape to Local Firm
April 17, 2019
- Nihon Generic to Mount Aggressive Sales Campaigns Taking Advantage of Group Synergy
April 16, 2019
- Takeda Nabs Top Japanese Analyst for Global IR Team
April 16, 2019
- Mitsubishi Tanabe ALS Drug Accepted for Review in China
April 16, 2019
- Daiichi Sankyo’s Lyrica Contender Tarlige Now Available
April 16, 2019
- Bayer Japan Ethical Drug Sales Slip 1% in 2018
April 15, 2019
- AstraZeneca Japan on Track for 4 Launches in 2019, Dependence on Crestor Fades
April 15, 2019
- Amgen Looks to Debut 3 Oncology Drugs in Next 3 Years: Global Commercial Chief
April 12, 2019
- Sanofi, Yakult Close Down Zaltrap Copromotion
April 12, 2019
- Sumitomo Dainippon to Soon Decide What to Do with ADHD Med Dasotraline after Setback
April 12, 2019
- Sumitomo Dainippon Shoots for Sales of 600 Billion Yen in FY2022, Revving Up “Post-Latuda” Pipeline Acquisition
April 12, 2019
- Mitsubishi Tanabe Joins Shonan iPark; 1st Pharma Company without Financial Ties to Takeda
April 12, 2019
- Shionogi Licenses Constipation Med to BioDelivery Sciences for Commercialization in US
April 12, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…